Yin Yong-Jun, Katz Vered, Salah Zaidoun, Maoz Myriam, Cohen Irit, Uziely Beatrice, Turm Hagit, Grisaru-Granovsky Sorina, Suzuki Hiromu, Bar-Shavit Rachel
Department of Oncology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.
Cancer Res. 2006 May 15;66(10):5224-33. doi: 10.1158/0008-5472.CAN-05-4234.
Protease-activated receptor 1 (PAR1) is emerging with distinct assignments in tumor biology. We show that tissue targeted overexpression of hPar1 in mice mammary glands results in precocious hyperplasia, characterized by a dense network of ductal side branching and accelerated proliferation. These glands exhibit increased levels of wnt-4 and wnt-7b and a striking beta-catenin stabilization. Nuclear localization of beta-catenin is observed in hPar1 transgenic mouse tissue sections but not in the wild-type, age-matched counterparts. PAR1 induces beta-catenin nuclear localization also in established epithelial tumor cell lines of intact beta-catenin system (transformed on the background of mismatch repair system; RKO cells). We propose hereby that PAR1-mediated beta-catenin stabilization is taking place primarily via the increase of Wnt expression. Enforced expression of a specific Wnt antagonist family member, secreted frizzled receptor protein 5 (SFRP5), efficiently inhibited PAR1-induced beta-catenin stabilization. Likewise, application of either SFRP2 or SFRP5 on epithelial tumor cells completely abrogated PAR1-induced beta-catenin nuclear accumulation. This takes place most likely via inhibition of Wnt signaling at the level of cell surface (forming a neutralizing complex of "Receptors-SFRP-Wnt"). Furthermore, depletion of hPar1 by small interfering RNA (siRNA) vectors markedly inhibited PAR1-induced Wnt-4. The striking stabilization of beta-catenin, inhibited by SFRPs on one hand and Wnt-4 silencing by hPar1 siRNA on the other hand, points to a novel role of hPar1 in Wnt-mediated beta-catenin stabilization. This link between PAR1 and beta-catenin may bear substantial implications both in developmental and tumor progression processes.
蛋白酶激活受体1(PAR1)在肿瘤生物学中有着不同的作用。我们发现,在小鼠乳腺中组织靶向过表达hPar1会导致早熟性增生,其特征是导管侧支形成密集网络且增殖加速。这些腺体中wnt-4和wnt-7b水平升高,β-连环蛋白显著稳定。在hPar1转基因小鼠组织切片中观察到β-连环蛋白的核定位,而在年龄匹配的野生型小鼠中未观察到。PAR1在完整β-连环蛋白系统的成熟上皮肿瘤细胞系(在错配修复系统背景下转化;RKO细胞)中也诱导β-连环蛋白核定位。我们在此提出,PAR1介导的β-连环蛋白稳定主要通过Wnt表达的增加来实现。特异性Wnt拮抗剂家族成员分泌型卷曲受体蛋白5(SFRP5)的强制表达有效抑制了PAR1诱导的β-连环蛋白稳定。同样,在上皮肿瘤细胞上应用SFRP2或SFRP5完全消除了PAR1诱导的β-连环蛋白核积累。这很可能是通过在细胞表面水平抑制Wnt信号传导(形成“受体-SFRP-Wnt”的中和复合物)来实现的。此外,小干扰RNA(siRNA)载体介导的hPar1缺失显著抑制了PAR1诱导的Wnt-4。一方面SFRP抑制β-连环蛋白的显著稳定,另一方面hPar1 siRNA使Wnt-4沉默,这表明hPar1在Wnt介导的β-连环蛋白稳定中具有新作用。PAR1与β-连环蛋白之间的这种联系可能在发育和肿瘤进展过程中都具有重要意义。